← Back to Search

Device

iRF System Hepatic Denervation for Type 2 Diabetes (DeLIVER Trial)

N/A
Waitlist Available
Research Sponsored by Metavention
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 30, 90, 180 and 365 days
Awards & highlights

Summary

This trial is testing a new device that uses radio waves to target nerves in the liver. It aims to help people with type 2 diabetes control their blood sugar better.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~30, 90, 180 and 365 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 30, 90, 180 and 365 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Rate of Serious Adverse Device Effects
Secondary study objectives
Adverse Event rate 365 days
Change in glycemic control - C-peptide
Change in glycemic control - FPG
+4 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Hepatic DenervationExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
iRF System Hepatic Denervation
2020
N/A
~20

Find a Location

Who is running the clinical trial?

MetaventionLead Sponsor
3 Previous Clinical Trials
121 Total Patients Enrolled
~3 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top